AXSM
VENTE TOTALE: 99 330 titres (~22 470 561,54 $ US)
- Insiders
- TABUTEAU HERRIOT
- Total bought
- —
- Total sold
- $22,470,562
- Last activity
- 2026-08-06
- Last synced
-
2026-08-12 09:47:22
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bearish signal Scored 2026-09-06
AXSM presents a weak overall profile: a low catalyst score (15) driven by heavy insider selling ($22.47M by the CEO with zero buys) and an earnings miss despite 46% revenue growth signals deteriorating market confidence.
The first sentence of the analysis written for AXSM on 2026-09-06 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 92.6% | 91.4% | 90.4% | 89.6% | 0.0% | |
| Ebit Margin | -27.7% | -72.7% | -85.7% | -359.3% | 0.0% | |
| Ebitda Margin | -26.3% | -70.7% | -83.1% | -350.5% | 0.0% | |
| Operating Profit Margin | -26.5% | -72.7% | -85.7% | -359.3% | 0.0% | |
| Pretax Profit Margin | -28.8% | -74.4% | -88.1% | -374.0% | 0.0% | |
| Continuous Operations Profit Margin | -28.7% | -74.5% | -88.4% | -374.0% | 0.0% | |
| Net Profit Margin | -28.7% | -74.5% | -88.4% | -374.0% | 0.0% | |
| Bottom Line Profit Margin | -28.7% | -74.5% | -88.4% | -374.0% | 0.0% | |
| Current Ratio | 1.555 | 2.108 | 3.632 | 2.544 | 3.751 | |
| Quick Ratio | 1.481 | 2.040 | 3.523 | 2.499 | 3.751 | |
| Solvency Ratio | -0.289 | -0.546 | -0.585 | -0.823 | -1.806 | |
| Cash Ratio | 0.852 | 1.370 | 2.781 | 2.080 | 3.749 | |
| Price To Earnings Ratio | -49.630 | -14.125 | -15.102 | -16.767 | -10.888 | |
| Price To Earnings Growth Ratio | 1.287 | -1.034 | -1.037 | -0.515 | -0.481 | |
| Forward Price To Earnings Growth Ratio | 1.287 | -1.034 | -1.037 | -0.515 | -0.481 | |
| Price To Earnings Diluted Ratio | -49.630 | -14.125 | -15.102 | -16.767 | -10.888 | |
| Price To Earnings Diluted Growth Ratio | 1.287 | -1.034 | -1.037 | -0.515 | -0.481 | |
| Price To Book Ratio | 102.903 | 71.104 | 18.931 | 28.623 | 90.928 | |
| Price To Sales Ratio | 14.230 | 10.511 | 13.361 | 62.669 | 0.000 | |
| Price To Free Cash Flow Ratio | -96.776 | -31.505 | -24.820 | -26.753 | -13.095 | |
| Price To Operating Cash Flow Ratio | -97.273 | -31.571 | -24.920 | -26.914 | -13.132 | |
| Debt To Assets Ratio | 0.350 | 0.339 | 0.317 | 0.286 | 0.566 | |
| Debt To Equity Ratio | 2.733 | 3.384 | 0.976 | 0.864 | 3.180 | |
| Debt To Capital Ratio | 0.732 | 0.772 | 0.494 | 0.464 | 0.761 | |
| Long Term Debt To Capital Ratio | 0.615 | 0.760 | 0.483 | 0.462 | 0.758 | |
| Financial Leverage Ratio | 7.813 | 9.971 | 3.080 | 3.026 | 5.616 | |
| Working Capital Turnover Ratio | 2.746 | 1.243 | 1.052 | 0.471 | 0.000 | |
| Operating Cash Flow Ratio | -0.247 | -0.558 | -1.045 | -1.207 | -4.692 | |
| Operating Cash Flow Sales Ratio | -0.146 | -0.333 | -0.536 | -2.328 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.005 | 1.002 | 1.004 | 1.006 | 1.003 | |
| Debt Service Coverage Ratio | -2.107 | -41.511 | -35.015 | -23.912 | -21.880 | |
| Interest Coverage Ratio | -25.810 | -42.710 | -35.925 | -24.512 | -21.894 | |
| Short Term Operating Cash Flow Coverage Ratio | -1.280 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -0.387 | -0.665 | -0.778 | -1.231 | -2.177 | |
| Capital Expenditure Coverage Ratio | -194.594 | -475.593 | -249.278 | -165.970 | -351.383 | |
| Dividend Paid And Capex Coverage Ratio | -194.594 | -475.593 | -249.278 | -165.970 | -351.383 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -53.570 | -14.422 | -15.181 | -17.273 | -11.109 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 92.6% | ▲1.2% | ▲19.8% |
| Ebit Margin | -27.7% | ▲45.0% | ▲81.3% |
| Ebitda Margin | -26.3% | ▲44.4% | ▲79.8% |
| Operating Profit Margin | -26.5% | ▲46.2% | ▲82.3% |
| Pretax Profit Margin | -28.8% | ▲45.7% | ▲84.3% |
| Continuous Operations Profit Margin | -28.7% | ▲45.8% | ▲84.4% |
| Net Profit Margin | -28.7% | ▲45.8% | ▲84.4% |
| Bottom Line Profit Margin | -28.7% | ▲45.8% | ▲84.4% |
| Current Ratio | 1.555 | ▼-0.553 | ▼-1.163 |
| Quick Ratio | 1.481 | ▼-0.559 | ▼-1.178 |
| Solvency Ratio | -0.289 | ▲0.257 | ▲0.521 |
| Cash Ratio | 0.852 | ▼-0.518 | ▼-1.314 |
| Price To Earnings Ratio | -49.630 | ▼-35.505 | ▼-28.328 |
| Price To Earnings Growth Ratio | 1.287 | ▲2.321 | ▲1.643 |
| Forward Price To Earnings Growth Ratio | 1.287 | ▲2.321 | ▲1.643 |
| Price To Earnings Diluted Ratio | -49.630 | ▼-35.505 | ▼-28.328 |
| Price To Earnings Diluted Growth Ratio | 1.287 | ▲2.321 | ▲1.643 |
| Price To Book Ratio | 102.903 | ▲31.799 | ▲40.405 |
| Price To Sales Ratio | 14.230 | ▲3.719 | ▼-5.924 |
| Price To Free Cash Flow Ratio | -96.776 | ▼-65.272 | ▼-58.186 |
| Price To Operating Cash Flow Ratio | -97.273 | ▼-65.703 | ▼-58.511 |
| Debt To Assets Ratio | 0.350 | ▲0.010 | ▼-0.022 |
| Debt To Equity Ratio | 2.733 | ▼-0.651 | ▲0.505 |
| Debt To Capital Ratio | 0.732 | ▼-0.040 | ▲0.088 |
| Long Term Debt To Capital Ratio | 0.615 | ▼-0.145 | ▼-0.001 |
| Financial Leverage Ratio | 7.812 | ▼-2.159 | ▲1.911 |
| Working Capital Turnover Ratio | 2.746 | ▲1.502 | ▲1.643 |
| Operating Cash Flow Ratio | -0.247 | ▲0.311 | ▲1.303 |
| Operating Cash Flow Sales Ratio | -0.146 | ▲0.187 | ▲0.522 |
| Free Cash Flow Operating Cash Flow Ratio | 1.005 | ▲0.003 | ▲0.001 |
| Debt Service Coverage Ratio | -2.107 | ▲39.405 | ▲22.779 |
| Interest Coverage Ratio | -25.810 | ▲16.900 | ▲4.360 |
| Short Term Operating Cash Flow Coverage Ratio | -1.280 | ▼-1.280 | ▼-1.024 |
| Operating Cash Flow Coverage Ratio | -0.387 | ▲0.278 | ▲0.661 |
| Capital Expenditure Coverage Ratio | -194.594 | ▲280.999 | ▲92.770 |
| Dividend Paid And Capex Coverage Ratio | -194.594 | ▲280.999 | ▲92.770 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -53.570 | ▼-39.148 | ▼-31.259 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $9.09B | $4.05B | $3.62B | $3.14B | $1.42B | |
| Enterprise value | $9.00B | $3.93B | $3.42B | $3.03B | $1.38B | |
| EV / Sales | 14.10x | 10.19x | 12.62x | 60.55x | 0.00x | |
| EV / Op. cash flow | -96.40x | -30.62x | -23.54x | -26.00x | -12.79x | |
| EV / Free cash flow | -95.91x | -30.55x | -23.45x | -25.85x | -12.76x | |
| EV / EBITDA | -53.57x | -14.42x | -15.18x | -17.27x | -11.11x | |
| Net debt / EBITDA | 0.49x | 0.45x | 0.89x | 0.60x | 0.29x | |
| Current ratio | 1.55x | 2.11x | 3.63x | 2.54x | 3.75x | |
| Income quality | 0.51x | 0.45x | 0.61x | 0.62x | 0.83x | |
| Graham net-net | -$2 | -$2 | $1 | $0 | $0 | |
| Tax burden | 99.7% | 100.0% | 100.4% | 100.0% | 100.0% | |
| Interest burden | 103.7% | 102.3% | 102.8% | 104.1% | 104.6% | |
| Working capital | $210.2M | $255.0M | $365.4M | $149.1M | $63.5M | |
| Invested capital | $283.6M | $319.9M | $438.4M | $220.2M | $64.4M | |
| Return on assets | -26.6% | -50.5% | -40.7% | -56.5% | -148.5% | |
| Operating ROA | -26.9% | -48.5% | -50.4% | -85.8% | -91.1% | |
| Return on tangible assets | -28.7% | -56.4% | -45.8% | -71.6% | -148.5% | |
| Return on equity | -207.5% | -503.8% | -125.3% | -170.8% | -834.3% | |
| Return on invested capital | -44.0% | -82.1% | -51.4% | -76.4% | -190.9% | |
| Return on capital employed | -54.4% | -82.9% | -51.6% | -76.5% | -192.7% | |
| Earnings yield | -2.0% | -7.1% | -6.6% | -6.0% | -9.2% | |
| Free cash flow yield | -1.0% | -3.2% | -4.0% | -3.7% | -7.6% | |
| Capex / Op. cash flow | -0.5% | -0.2% | -0.4% | -0.6% | -0.3% | |
| Capex / Depreciation | 5.3% | 3.4% | 8.5% | 15.9% | 405.3% | |
| Capex / Sales | 0.1% | 0.1% | 0.2% | 1.4% | 0.0% | |
| SG&A / Sales | 89.4% | 106.7% | 119.4% | 318.3% | 0.0% | |
| R&D / Sales | 28.7% | 48.5% | 36.2% | 115.8% | 0.0% | |
| Stock comp / Sales | 14.7% | 22.1% | 23.1% | 75.4% | 0.0% | |
| Intangibles / Total assets | 7.6% | 10.4% | 11.1% | 21.1% | 0.0% | |
| Days sales outstanding | 128d | 134d | 128d | 275d | 0d | |
| Days payables outstanding | 504d | 789d | 570d | 2711d | 0d | |
| Operating cycle | 343d | 307d | 340d | 578d | 0d | |
| Cash conversion cycle | -161d | -482d | -230d | -2132d | 0d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+124.1%EV / Sales ▲+38.3%EV / EBITDA ▼-271.4%EV / Op. cash flow ▼-65.782Earnings yield ▲+0.051
Profitability
Return on equity ▲+2.963Return on assets ▲+0.240Return on invested capital ▲+0.382Return on capital employed ▲+0.285Operating ROA ▲+0.216Income quality ▲+0.063Tax burden ▼-0.003
Efficiency
Days sales outstanding ▼-6.066Days payables outstanding ▼-285.252Operating cycle ▲+36.292Cash conversion cycle ▲+321.544Capex / Sales +0.000R&D / Sales ▼-0.198
Balance-sheet strength
Current ratio ▼-0.553Net debt / EBITDA ▲+0.037Working capital ▼-44810000.000Invested capital ▼-36294000.000Intangibles / Total assets ▼-0.027
Change over 5 years
Valuation
Market cap ▲+539.3%EV / Sales n/aEV / EBITDA ▼-382.2%EV / Op. cash flow ▼-83.607Earnings yield ▲+0.072
Profitability
Return on equity ▲+6.268Return on assets ▲+1.220Return on invested capital ▲+1.469Return on capital employed ▲+1.383Operating ROA ▲+0.642Income quality ▼-0.320Tax burden ▼-0.003
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▼-2.196Net debt / EBITDA ▲+0.191Working capital ▲+146697044.000Invested capital ▲+219172036.000Intangibles / Total assets n/a
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-08-11 Axsome''s Q2 Earnings Meet Estimates, Auvelity Drives Y/Y Revenues AXSM''s Q2 earnings meet estimates, but revenues miss forecasts. Auvelity and other product sales drive year-over-year revenues.
- 2026-08-11 Axsome Therapeutics Q2 Earnings Review: I Just Can''t See The Value Proposition Axsome Therapeutics, Inc. reported Q2 2026 net product revenue growth of 46% year-on-year, but rising SG&A costs mostly offset commercial gains. Auvelity drove most revenues, benefiting from new Alzheimer''s agitation indication and expanded sales force, yet profitability remains elusive. Management reiterates ambitious ~$8bn peak sales target for Auvelity, but current revenue trajectory and market dynamics cast doubt on achievability.
- 2026-08-10 Axsome Therapeutics, Inc. (AXSM) Q2 2026 Earnings Call Transcript Axsome Therapeutics, Inc. (AXSM) Q2 2026 Earnings Call Transcript
- 2026-08-10 Axsome (AXSM) Reports Q2 Earnings: What Key Metrics Have to Say While the top- and bottom-line numbers for Axsome (AXSM) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
- 2026-08-10 Axsome Therapeutics (AXSM) Reports Q2 Loss, Misses Revenue Estimates Axsome Therapeutics (AXSM) came out with a quarterly loss of $0.99 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.92 per share a year ago.
- 2026-08-10 Axsome Therapeutics Q2 Earnings Call Highlights Axsome Therapeutics NASDAQ: AXSM reported second-quarter 2026 net product revenue of $218 million, up 46% from a year earlier, as sales of AUVELITY and SUNOSI increased and prescription demand for SYMBRAVO continued to build.
- 2026-08-10 Axsome Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update Total 2Q 2026 net product revenue of $218.4 million, representing 46% year-over-year growth AUVELITY® 2Q 2026 net product sales of $180.3 million, representing 51% year-over-year growth SUNOSI® 2Q 2026 net product revenue of $35.8 million, representing 20% year-over-year growth SYMBRAVO® 2Q 2026 net product sales of $2.3 million AUVELITY launched for treatment of agitation associated with dementia due to Alzheimer''s disease in June 2026 NDA submission for AXS-12 for cataplexy in narcolepsy accepted by the FDA with PDUFA target action date of May 1, 2027 FOCUS-2 and FOCUS-3 Phase 3 trials of solriamfetol in children and adolescents with ADHD initiated Company to host conference call today at 8:00 AM Eastern NEW YORK, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced financial results for the second quarter of 2026 and provided a general business update. “The second quarter was highly productive for Axsome.
- 2026-08-10 Axsome Therapeutics (NASDAQ:AXSM) CEO Sells $997,007.00 in Stock Axsome Therapeutics, Inc. (NASDAQ: AXSM - Get Free Report) CEO Herriot Tabuteau sold 4,660 shares of the business''s stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $213.95, for a total value of $997,007.00. Following the completion of the transaction, the chief executive officer directly owned 7,229 shares
- 2026-08-08 Assenagon Asset Management S.A. Cuts Stock Holdings in Axsome Therapeutics, Inc. $AXSM Assenagon Asset Management S.A. lowered its holdings in Axsome Therapeutics, Inc. (NASDAQ: AXSM) by 47.5% in the undefined quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 454,682 shares of the company''s stock after selling 411,276 shares during the quarter. Assenagon Asset Management S.A.
- 2026-08-05 Countdown to Axsome (AXSM) Q2 Earnings: Wall Street Forecasts for Key Metrics Looking beyond Wall Street''s top-and-bottom-line estimate forecasts for Axsome (AXSM), delve into some of its key metrics to gain a deeper insight into the company''s potential performance for the quarter ended June 2026.